Pages that link to "Q45874048"
Jump to navigation
Jump to search
The following pages link to Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain (Q45874048):
Displaying 50 items.
- Gutless adenovirus: last-generation adenovirus for gene therapy (Q28277560) (← links)
- In vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system. (Q33216908) (← links)
- Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. (Q33364523) (← links)
- Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging (Q33641230) (← links)
- Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS (Q33894621) (← links)
- Gene transfer into rat brain using adenoviral vectors. (Q33904294) (← links)
- Gene delivery with viral vectors for cerebrovascular diseases (Q33917592) (← links)
- Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders (Q33985663) (← links)
- Recent advances in the pharmacology of neurological gene therapy (Q33985688) (← links)
- Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology (Q34069598) (← links)
- Neuronal expression of the transcription factor Gli1 using the Talpha1 alpha-tubulin promoter is neuroprotective in an experimental model of Parkinson's disease. (Q34074765) (← links)
- Molecular therapy in a model neuroendocrine disease: developing clinical gene therapy for pituitary tumours. (Q34135050) (← links)
- Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain (Q34193457) (← links)
- Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. (Q34233124) (← links)
- Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity (Q34365087) (← links)
- Genetic engineering within the adult brain: implications for molecular approaches to behavioral neuroscience (Q34375860) (← links)
- Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. (Q34546483) (← links)
- Impact of E1 and Cre on adenovirus vector amplification: developing MDCK CAV-2-E1 and E1-Cre transcomplementing cell lines. (Q34658351) (← links)
- Gene therapy for cerebral vascular disease: update 2003. (Q35045240) (← links)
- Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction. (Q35069550) (← links)
- Gene therapy for pituitary tumors: from preclinical models to clinical implementation (Q35074544) (← links)
- Current and future strategies for the treatment of malignant brain tumors. (Q35095713) (← links)
- Progress and problems with the use of viral vectors for gene therapy (Q35120176) (← links)
- Molecular basis of the inflammatory response to adenovirus vectors (Q35131213) (← links)
- Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences (Q35131222) (← links)
- Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A. (Q35225590) (← links)
- Gene therapy for the nervous system: challenges and new strategies (Q35340196) (← links)
- Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro (Q35870480) (← links)
- Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation. (Q35999648) (← links)
- Immune problems in central nervous system cell therapy. (Q36045396) (← links)
- Regulatable gene expression systems for gene therapy applications: progress and future challenges (Q36157542) (← links)
- Adenoviral-mediated gene transfer into the canine brain in vivo (Q36172992) (← links)
- Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells. (Q36274402) (← links)
- Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms. (Q36367568) (← links)
- Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma (Q36411432) (← links)
- Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system (Q36464407) (← links)
- One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. (Q36498762) (← links)
- Immunology of neurological gene therapy: how T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses (Q36498768) (← links)
- Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions (Q36498773) (← links)
- Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial (Q36534329) (← links)
- Regulatable gene expression systems for gene therapy (Q36569912) (← links)
- Efficacy of nonviral gene transfer in the canine brain (Q36658314) (← links)
- Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production. (Q36960666) (← links)
- Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. (Q36994063) (← links)
- Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity (Q37403279) (← links)
- AAV for pain: steps towards clinical translation (Q37406976) (← links)
- Viral vectors for gene delivery to the central nervous system (Q37946113) (← links)
- Gene therapy approaches for lysosomal storage disorders, a good model for the treatment of mendelian diseases (Q37994717) (← links)
- Molecular neurosurgery: vectors and vector delivery strategies (Q37998570) (← links)
- Recent gene therapy advancements for neurological diseases. (Q38085469) (← links)